Citigroup Inc Incyte Corp Call Options Transaction History

Citigroup Inc

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 10, 2024	BUY	$56.55 - $66.59 $1.46 Million - $1.72 Million	25,800 Added 86.29%	55,700 $3.17 Million
Q4 2023 Feb 09, 2024	BUY	$52.16 - $64.19 $1.56 Million - $1.92 Million	29,900 New	29,900 $1.88 Million
Q4 2022 Feb 09, 2023	SELL	$67.18 - $84.11 $335,900 - $420,550	-5,000 Reduced 16.67%	25,000 $2.01 Million
Q3 2022 Nov 10, 2022	BUY	$66.18 - $82.86 $1.99 Million - $2.49 Million	30,000 New	30,000 $2 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.